Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy-Reference-Cited by-同舟云学术

Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy

Published:2024-02-15 Issue:7 Volume:390 Page:584-586
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Verdun Nicole¹,Marks Peter¹^ORCID

Affiliation:

1. From the Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD.

Publisher

Massachusetts Medical Society

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMp2400209

Reference5 articles.

1. CAR T-cell therapy in autoimmune diseases

2. How I treat refractory CRS and ICANS after CAR T-cell therapy.;Jain MD;Blood,2023

3. Food and Drug Administration. Considerations for the development of chimeric antigen receptor (CAR) T cell products. March 2022 (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-development-chimeric-antigen-receptor-car-t-cell-products).

4. Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives

5. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chimeric antigen receptor (CAR) T-cell therapy: Harnessing extracellular vesicles for enhanced efficacy;Pharmacological Research;2024-10

2. CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia;2024-09-03

3. The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?;International Journal of Molecular Sciences;2024-09-01

4. Off-the-shelf CAR-T cells could prove paradigm shifting for autoimmune diseases;Cell;2024-09

5. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis;Cell;2024-09